OVERSEA CHINESE BANKING Corp Ltd Sells 5,341 Shares of Moderna, Inc. (NASDAQ:MRNA)

OVERSEA CHINESE BANKING Corp Ltd lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 18.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,504 shares of the company’s stock after selling 5,341 shares during the period. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Moderna were worth $943,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. State Street Corp grew its holdings in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the period. Geode Capital Management LLC grew its holdings in shares of Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after acquiring an additional 178,115 shares during the period. Wellington Management Group LLP grew its holdings in shares of Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after acquiring an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after acquiring an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after acquiring an additional 178,939 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Down 1.4 %

Moderna stock opened at $33.32 on Thursday. The business has a fifty day moving average of $35.31 and a two-hundred day moving average of $46.45. The firm has a market cap of $12.86 billion, a P/E ratio of -3.59 and a beta of 1.86. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47.

Analyst Upgrades and Downgrades

MRNA has been the topic of several analyst reports. Citigroup initiated coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 target price on the stock. Evercore ISI set a $50.00 target price on Moderna in a research report on Friday, February 14th. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and lowered their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Bank of America lowered their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Finally, Morgan Stanley lowered their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $59.60.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.